Transactions
4
Insider / SUPERNUS PHARMACEUTICALS, INC.
Barlow Carrolee
Director at SUPERNUS PHARMACEUTICALS, INC.
- Ticker
- SUPN
- First filing on record
- February 20, 2026
- Latest trade on record
- February 24, 2026
- SEC filings
- EDGAR ↗
Barlow Carrolee, Director at SUPERNUS PHARMACEUTICALS, INC., has disclosed 4 transactions in SUPN since February 20, 2026: 0 purchases (0 open-market buys) and 0 sales, worth about $0 at the reported prices. The latest was filed February 25, 2026, 1 day after the trade.
Open-market buys
0
Sales
0
Avg. disclosure lag
1.5d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Barlow Carrolee reported 4 transactions that were neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 2 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 3 | 12,441 | — |
| D | Sale back to the company | 1 | 4,475 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 4 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| SUPN | Option / conversion D | February 24, 2026 | February 25, 2026 | 1d | 4,475 | — | — | derivative | Form 4 ↗ | |
| SUPN | Other A | February 24, 2026 | February 25, 2026 | 1d | 4,475 | — | — | Form 4 ↗ | ||
| SUPN | Other A | February 18, 2026 | February 20, 2026 | 2d | 4,977 | — | — | derivative | Form 4 ↗ | |
| SUPN | Other A | February 18, 2026 | February 20, 2026 | 2d | 2,989 | — | — | derivative | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| February 25, 2026 | Form 4 | 0001745316-26-000004 | 2 | published | EDGAR ↗ |
| February 20, 2026 | Form 4 | 0001745316-26-000002 | 2 | published | EDGAR ↗ |
Other insiders at SUPERNUS PHARMACEUTICALS, INC.
- Bhatt Padmanabh P. Sr. VP of IP, CSO 44 rows
- Khattar Jack A. President, CEO 33 rows
- Mottola Frank SVP, Chief Tech. Ops. Officer 29 rows
- DEC TIMOTHY C Senior Vice-President & CFO 26 rows
- Rubin Jonathan SVP, Chief Medical Officer 18 rows
- Horich William Todd SVP, Commercial Operations 11 rows
- GEMAYEL GEORGES Director 10 rows
- NEWHALL CHARLES W III Director 8 rows
- Hudson Frederick M. Director 7 rows
- Sensenig Bethany Director 6 rows
Everyone on file, with contracts and lobbying under the company's name: SUPERNUS PHARMACEUTICALS, INC..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 2 | 4 | February 20, 2026 | February 25, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.